Patented

The head of the Chemistry Department, Prof. Dr. Muhammad Nazim Bahjat, and the teaching assistant, Dr. Zainab Nizar Jawad, from the Biology Department at the College of Education for Pure Sciences at the University of Kerbala, obtained a patent from the Central Organization for Standardization and Quality Control to enable them to manufacture a new drug compound and use it to treat And inhibiting the speed of spread of lung cancer cells.
The patent included measuring the rate of release of the innovative treatment in different acid parameters of beaver solutions in the laboratory. These acid parameters express the acidity of human internal organ fluids, such as the acidity of the stomach and small intestine, whether outside the living cell or inside the living cell. The treatment proved successful in releasing and The drug is released from the new prepared nanocomposite in the stomach at a very small rate and in the intestine at a very high rate.
The patent also consisted of studying the nature of the interactions between the drug loaded on chitosan and the protein that causes the growth and spread of the lung cancer line (A549). The amino acids that make up the protein that attract with the drug were also identified. The characteristics of the biological activity (cell toxicity analyses) were also studied. The anti-proliferative effect of cancer cells was evaluated using nano-chitosan loaded with the drug mefenamic acid.
The patent aimed to conclude that the nano-drug composite (mefenamic acid drug loaded on nano-chitosan) is a suitable and promising strategy for developing an effective drug delivery system for clinical application against lung cancers.